Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine + esketamine dosing for hysteroscopy anesthesia
ChiCTR2500101056Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of oliceridine and esketamine in None (3 arms), sponsored by Changhai Hospital. Primary endpoint: Median effective dose (ED50) of esketamine in each group. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
oliceridineesketamine
Beyond the preview
Go deeper on ChiCTR2500101056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101056.